Recursion Pharmaceuticals Inc vs Sprott Uranium Miners ETF — how do they compare? Recursion Pharmaceuticals Inc trades at $3.36 (market cap $1.81B), while Sprott Uranium Miners ETF trades at $55.96. The key difference: Sprott Uranium Miners ETF is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| RXRX | URNM | |
|---|---|---|
Market Cap | $1.81B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $6.79 | $83.99 |
52-Week Low | $2.84 | $44.14 |
Enterprise Value | $1.33B | — |
Trailing returns across standard periods
Latest headlines on both assets
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →URNM is a pure-play ETF that invests in the global uranium industry. It provides exposure to companies involved in the mining, exploration, and production of uranium, as well as physical uranium holdings, with top assets like Cameco, Uranium Energy Corp, and the Sprott Physical Uranium Trust.
Read more on URNM →